Cumberland Pharmaceuticals Inc. Reports Q2 2026 Financial Results

What Happened

• Cumberland Pharmaceuticals Inc. filed a Form 8-K on August 4, 2026 (Item 2.02) announcing a company update and its financial results for the three- and six-month periods ended June 30, 2026. The company’s press release with those results is attached as Exhibit 99.1 to the filing. The report was signed by CFO John Hamm.

Key Details

• Filing date: August 4, 2026; reporting Item: 2.02 (Results of Operations and Financial Condition).
• The press release containing the quarterly results and company update is included as Exhibit 99.1 (Item 9.01).
• The results cover the three and six months ended June 30, 2026 (i.e., Q2 2026 and YTD six-month period).
• The Form 8-K was signed by John Hamm, Chief Financial Officer.

Why It Matters

• This 8-K signals the company has released its latest quarterly results (earnings/revenue and other operating metrics). Investors should read the attached press release (Exhibit 99.1) for the detailed figures—revenue, net income/loss, EPS, and any management commentary or guidance—that could affect the stock.
• Because the filing only references the press release, the specific financial impacts and any changes to outlook are contained in Exhibit 99.1; review that document to assess near-term implications for valuation or investment decisions.